Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Irreversible electroporation in focal therapy for prostate cancer: current status and future directions.

Prostate international·2026
Same author

Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials.

European urology oncology·2026
Same author

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.

JAMA oncology·2026
Same author

From 18F-choline to prostate-specific membrane antigen PET: lessons from early multiparametric kinetic modelling in prostate cancer.

Nuclear medicine communications·2026
Same author

Nephron Sparing Treatment (NEST) for small renal masses: understanding patients' and clinicians' experiences of a cohort-embedded randomised control trial.

Pilot and feasibility studies·2026
Same author

Retraction notice to "Stiffness memory of indirectly 3D-printed elastomer nanohybrid regulates chondrogenesis and osteogenesis of human mesenchymal stem cells" [Biomaterials 186 (2018) 18884].

Biomaterials·2026
Same journal

Pediatric andrology: bridging pediatric urology and reproductive medicine.

Current opinion in urology·2026
Same journal

Current impact of simulation-based surgical training in urology: a review from the European School of Urology and the European Association of Urology Endourology Section.

Current opinion in urology·2026
Same journal

Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity.

Current opinion in urology·2026
Same journal

Role and relevance of genetic testing in patients with kidney stones: a review from EAU Section of Endourology.

Current opinion in urology·2026
Same journal

Advances in evaluating and delivering nontechnical skills training: The use of simulation, robotics, artificial intelligence and virtual reality.

Current opinion in urology·2026
Same journal

Educating for a sustainable future: faculty and student perspectives and a review of environmental sustainability in medical education - an EAU endourology study.

Current opinion in urology·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Behaviour modification and benign prostatic hyperplasia: replacement for medications.

Tet Yap1, Mark Emberton

  • 1Department of Urology, St. Bartholomews Hospital, Barts and London NHS Trust, West Smithfield, London, UK.

Current Opinion in Urology
|November 6, 2009
PubMed
Summary
This summary is machine-generated.

A structured self-management program for benign prostatic hyperplasia (BPH) significantly reduced lower urinary tract symptoms compared to standard care. This approach may improve patient quality of life and reduce healthcare costs.

More Related Videos

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jun 19, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Area of Science:

  • Urology
  • Behavioral Medicine

Background:

  • Benign prostatic hyperplasia (BPH) is a prevalent chronic condition with significant treatment costs.
  • Behavioral treatments for BPH are under-assessed, despite potential suitability for many uncomplicated patients.

Purpose of the Study:

  • To summarize recent knowledge on behavioral interventions for BPH.
  • To assess a randomized controlled trial (RCT) of a self-management program for BPH.

Main Methods:

  • Review of recent data on behavioral interventions for BPH.
  • Analysis of a randomized controlled trial (RCT) evaluating a structured self-management program.

Main Results:

  • The self-management program significantly reduced lower urinary tract symptom severity, nocturia, urgency, and frequency compared to standard care.
  • The program's effectiveness may stem from changes in bladder capacity rather than fluid management.
  • Further research into the mechanisms and broader application of behavioral interventions for BPH is needed.

Conclusions:

  • Self-management program elements can be integrated into watchful waiting strategies.
  • Patient quality of life improvement and reduced healthcare financial burden are potential benefits.
  • Multidisciplinary team promotion is crucial for implementing self-management; larger trials are needed to address RCT limitations.